ID   PMYT1_HUMAN             Reviewed;         499 AA.
AC   Q99640; B3KUN8; B4DXD4; D3DUA4; F8W164; I3L1V2; O14731; Q7LE24; Q8TCM9;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   12-OCT-2022, entry version 195.
DE   RecName: Full=Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Myt1 kinase;
GN   Name=PKMYT1; Synonyms=MYT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ACTIVITY REGULATION.
RX   PubMed=9268380; DOI=10.1074/jbc.272.35.22300;
RA   Booher R.N., Holman P.S., Fattaey A.;
RT   "Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not
RT   Cdk2 activity.";
RL   J. Biol. Chem. 272:22300-22306(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9001210; DOI=10.1128/mcb.17.2.571;
RA   Liu F., Stanton J.J., Wu Z., Piwnica-Worms H.;
RT   "The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14
RT   and localizes to the endoplasmic reticulum and Golgi complex.";
RL   Mol. Cell. Biol. 17:571-583(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Testis, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-140; ARG-417 AND
RP   ALA-445.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 403-499 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   INTERACTION WITH PIN1.
RX   PubMed=9499405; DOI=10.1101/gad.12.5.706;
RA   Shen M., Stukenberg P.T., Kirschner M.W., Lu K.P.;
RT   "The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates
RT   mitosis-specific phosphoproteins.";
RL   Genes Dev. 12:706-720(1998).
RN   [9]
RP   PHOSPHORYLATION, COMPONENT OF CDC2-CCNB1 COMPLEX, INTERACTION WITH PIN1,
RP   AND MUTAGENESIS OF ASP-251.
RX   PubMed=10504341; DOI=10.1242/jcs.112.19.3361;
RA   Wells N.J., Watanabe N., Tokusumi T., Jiang W., Verdecia M.A., Hunter T.;
RT   "The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with
RT   Cdc2 complexes and is required for inhibition of G(2)/M progression.";
RL   J. Cell Sci. 112:3361-3371(1999).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF ASN-238 AND 486-ARG--LEU-488.
RX   PubMed=10373560; DOI=10.1128/mcb.19.7.5113;
RA   Liu F., Rothblum-Oviatt C., Ryan C.E., Piwnica-Worms H.;
RT   "Overproduction of human Myt1 kinase induces a G2 cell cycle delay by
RT   interfering with the intracellular trafficking of Cdc2-cyclin B1
RT   complexes.";
RL   Mol. Cell. Biol. 19:5113-5123(1999).
RN   [11]
RP   PHOSPHORYLATION AT SER-426 AND THR-495.
RX   PubMed=12738781; DOI=10.1074/jbc.c300126200;
RA   Nakajima H., Toyoshima-Morimoto F., Taniguchi E., Nishida E.;
RT   "Identification of a consensus motif for Plk (Polo-like kinase)
RT   phosphorylation reveals Myt1 as a Plk1 substrate.";
RL   J. Biol. Chem. 278:25277-25280(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-17; SER-94; SER-469 AND
RP   THR-495, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120; SER-469 AND SER-473, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT THR-17 AND SER-160, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40; SER-94; SER-120; SER-143;
RP   SER-469 AND SER-482, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-103; CYS-140; HIS-246 AND LYS-351.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as a negative regulator of entry into mitosis (G2 to M
CC       transition) by phosphorylation of the CDK1 kinase specifically when
CC       CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1
CC       predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be
CC       involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree,
CC       however tyrosine kinase activity is unclear and may be indirect. May be
CC       a downstream target of Notch signaling pathway during eye development.
CC       {ECO:0000269|PubMed:10373560, ECO:0000269|PubMed:9001210}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Negatively regulated by hyperphosphorylation
CC       during mitosis. The hyperphosphorylated form does not associate with
CC       CCNB1-CDC2 complexes. The PLK1 protein kinase may be required for
CC       mitotic phosphorylation. {ECO:0000269|PubMed:9268380}.
CC   -!- SUBUNIT: Interacts with CDC2-CCNB1 complex. Can also interact with PIN1
CC       when phosphorylated by CDC2-CCNB1. {ECO:0000269|PubMed:10504341,
CC       ECO:0000269|PubMed:9499405}.
CC   -!- INTERACTION:
CC       Q99640; P14635: CCNB1; NbExp=6; IntAct=EBI-495308, EBI-495332;
CC       Q99640; P06493: CDK1; NbExp=7; IntAct=EBI-495308, EBI-444308;
CC       Q99640-2; O95870: ABHD16A; NbExp=3; IntAct=EBI-12257782, EBI-348517;
CC       Q99640-2; P07766: CD3E; NbExp=3; IntAct=EBI-12257782, EBI-1211297;
CC       Q99640-2; P11912: CD79A; NbExp=3; IntAct=EBI-12257782, EBI-7797864;
CC       Q99640-2; P56748: CLDN8; NbExp=3; IntAct=EBI-12257782, EBI-10215641;
CC       Q99640-2; Q9GZR5: ELOVL4; NbExp=3; IntAct=EBI-12257782, EBI-18535450;
CC       Q99640-2; Q969F0: FATE1; NbExp=3; IntAct=EBI-12257782, EBI-743099;
CC       Q99640-2; Q9H400: LIME1; NbExp=3; IntAct=EBI-12257782, EBI-2830566;
CC       Q99640-2; Q8N386: LRRC25; NbExp=3; IntAct=EBI-12257782, EBI-11304917;
CC       Q99640-2; Q5SR56: MFSD14B; NbExp=3; IntAct=EBI-12257782, EBI-373355;
CC       Q99640-2; Q6N075: MFSD5; NbExp=3; IntAct=EBI-12257782, EBI-3920969;
CC       Q99640-2; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-12257782, EBI-10192441;
CC       Q99640-2; Q14973: SLC10A1; NbExp=3; IntAct=EBI-12257782, EBI-3923031;
CC       Q99640-2; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-12257782, EBI-10262251;
CC       Q99640-2; Q96IK0: TMEM101; NbExp=3; IntAct=EBI-12257782, EBI-3922699;
CC       Q99640-2; Q8NBD8: TMEM229B; NbExp=3; IntAct=EBI-12257782, EBI-12195227;
CC       Q99640-2; Q9Y320: TMX2; NbExp=3; IntAct=EBI-12257782, EBI-6447886;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:9001210}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9001210}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:9001210}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9001210}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q99640-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99640-2; Sequence=VSP_045699;
CC       Name=3;
CC         IsoId=Q99640-3; Sequence=VSP_046846;
CC       Name=4;
CC         IsoId=Q99640-4; Sequence=VSP_046847;
CC   -!- DOMAIN: The membrane-association motif is essential for the
CC       localization to membrane of Golgi stack. According to some authors, it
CC       is a transmembrane domain; the existence of a transmembrane region is
CC       however unproven.
CC   -!- PTM: Autophosphorylated. Phosphorylated by CDC2-CCNB1 complexes on
CC       undefined serine and threonine residues. The phosphorylation by CDC2-
CC       CCNB1 complexes may inhibit the catalytic activity.
CC       {ECO:0000269|PubMed:10504341, ECO:0000269|PubMed:12738781}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD28540.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pkmyt1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF014118; AAB71843.1; -; mRNA.
DR   EMBL; U56816; AAC50949.1; -; mRNA.
DR   EMBL; AK097642; BAG53500.1; -; mRNA.
DR   EMBL; AK098452; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK301926; BAG63346.1; -; mRNA.
DR   EMBL; AF549406; AAN40703.1; -; Genomic_DNA.
DR   EMBL; AC004233; AAC04478.1; -; Genomic_DNA.
DR   EMBL; AC004235; AAC04477.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85439.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85440.1; -; Genomic_DNA.
DR   EMBL; AL713779; CAD28540.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS10486.1; -. [Q99640-1]
DR   CCDS; CCDS45391.1; -. [Q99640-2]
DR   CCDS; CCDS58414.1; -. [Q99640-3]
DR   CCDS; CCDS58415.1; -. [Q99640-4]
DR   RefSeq; NP_001245379.1; NM_001258450.1. [Q99640-4]
DR   RefSeq; NP_001245380.1; NM_001258451.1. [Q99640-3]
DR   RefSeq; NP_004194.3; NM_004203.4. [Q99640-1]
DR   RefSeq; NP_872629.1; NM_182687.2. [Q99640-2]
DR   RefSeq; XP_011521036.1; XM_011522734.2. [Q99640-1]
DR   RefSeq; XP_011521037.1; XM_011522735.2. [Q99640-3]
DR   RefSeq; XP_011521038.1; XM_011522736.2. [Q99640-3]
DR   PDB; 3P1A; X-ray; 1.70 A; A=75-362.
DR   PDB; 5VCV; X-ray; 1.92 A; A=75-362.
DR   PDB; 5VCW; X-ray; 2.25 A; A/B=75-362.
DR   PDB; 5VCX; X-ray; 2.70 A; A=75-362.
DR   PDB; 5VCY; X-ray; 1.56 A; A=75-362.
DR   PDB; 5VCZ; X-ray; 1.50 A; A=75-362.
DR   PDB; 5VD0; X-ray; 2.13 A; A=75-362.
DR   PDB; 5VD1; X-ray; 1.70 A; A=75-362.
DR   PDB; 5VD3; X-ray; 1.80 A; A=75-362.
DR   PDBsum; 3P1A; -.
DR   PDBsum; 5VCV; -.
DR   PDBsum; 5VCW; -.
DR   PDBsum; 5VCX; -.
DR   PDBsum; 5VCY; -.
DR   PDBsum; 5VCZ; -.
DR   PDBsum; 5VD0; -.
DR   PDBsum; 5VD1; -.
DR   PDBsum; 5VD3; -.
DR   AlphaFoldDB; Q99640; -.
DR   SMR; Q99640; -.
DR   BioGRID; 114544; 149.
DR   ELM; Q99640; -.
DR   IntAct; Q99640; 44.
DR   MINT; Q99640; -.
DR   STRING; 9606.ENSP00000262300; -.
DR   BindingDB; Q99640; -.
DR   ChEMBL; CHEMBL3984; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q99640; -.
DR   GuidetoPHARMACOLOGY; 2167; -.
DR   iPTMnet; Q99640; -.
DR   PhosphoSitePlus; Q99640; -.
DR   BioMuta; PKMYT1; -.
DR   DMDM; 55976573; -.
DR   EPD; Q99640; -.
DR   jPOST; Q99640; -.
DR   MassIVE; Q99640; -.
DR   MaxQB; Q99640; -.
DR   PaxDb; Q99640; -.
DR   PeptideAtlas; Q99640; -.
DR   PRIDE; Q99640; -.
DR   ProteomicsDB; 29565; -.
DR   ProteomicsDB; 46754; -.
DR   ProteomicsDB; 5428; -.
DR   ProteomicsDB; 78372; -. [Q99640-1]
DR   Antibodypedia; 23946; 527 antibodies from 33 providers.
DR   DNASU; 9088; -.
DR   Ensembl; ENST00000262300.13; ENSP00000262300.8; ENSG00000127564.17. [Q99640-1]
DR   Ensembl; ENST00000440027.6; ENSP00000397739.2; ENSG00000127564.17. [Q99640-2]
DR   Ensembl; ENST00000573944.5; ENSP00000459123.1; ENSG00000127564.17. [Q99640-3]
DR   Ensembl; ENST00000574385.5; ENSP00000458943.1; ENSG00000127564.17. [Q99640-3]
DR   Ensembl; ENST00000574730.5; ENSP00000460868.1; ENSG00000127564.17. [Q99640-4]
DR   GeneID; 9088; -.
DR   KEGG; hsa:9088; -.
DR   MANE-Select; ENST00000262300.13; ENSP00000262300.8; NM_004203.5; NP_004194.3.
DR   UCSC; uc002csm.4; human. [Q99640-1]
DR   CTD; 9088; -.
DR   DisGeNET; 9088; -.
DR   GeneCards; PKMYT1; -.
DR   HGNC; HGNC:29650; PKMYT1.
DR   HPA; ENSG00000127564; Tissue enhanced (bone marrow, testis).
DR   MIM; 602474; gene.
DR   neXtProt; NX_Q99640; -.
DR   OpenTargets; ENSG00000127564; -.
DR   PharmGKB; PA385; -.
DR   VEuPathDB; HostDB:ENSG00000127564; -.
DR   eggNOG; KOG0601; Eukaryota.
DR   GeneTree; ENSGT00940000159427; -.
DR   InParanoid; Q99640; -.
DR   OMA; PCTPPKD; -.
DR   OrthoDB; 1063695at2759; -.
DR   PhylomeDB; Q99640; -.
DR   TreeFam; TF101087; -.
DR   PathwayCommons; Q99640; -.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   Reactome; R-HSA-69478; G2/M DNA replication checkpoint.
DR   SignaLink; Q99640; -.
DR   SIGNOR; Q99640; -.
DR   BioGRID-ORCS; 9088; 786 hits in 1115 CRISPR screens.
DR   ChiTaRS; PKMYT1; human.
DR   EvolutionaryTrace; Q99640; -.
DR   GeneWiki; PKMYT1; -.
DR   GenomeRNAi; 9088; -.
DR   Pharos; Q99640; Tchem.
DR   PRO; PR:Q99640; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q99640; protein.
DR   Bgee; ENSG00000127564; Expressed in right testis and 112 other tissues.
DR   ExpressionAtlas; Q99640; baseline and differential.
DR   Genevisible; Q99640; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0051321; P:meiotic cell cycle; IBA:GO_Central.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR016235; Tyr/Thr_kinase_Cdc2_inhib.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000567; TYPK_Myt1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
KW   Endoplasmic reticulum; Golgi apparatus; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..499
FT                   /note="Membrane-associated tyrosine- and threonine-specific
FT                   cdc2-inhibitory kinase"
FT                   /id="PRO_0000086573"
FT   DOMAIN          110..359
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..29
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          42..72
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          398..499
FT                   /note="Interaction with PIN1"
FT   REGION          437..499
FT                   /note="Interaction with CDC2-CCNB1"
FT   REGION          451..485
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           382..398
FT                   /note="Membrane-association motif"
FT   COMPBIAS        11..26
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..62
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        233
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         116..124
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         139
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         238
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250"
FT   BINDING         251
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         17
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         94
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         120
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         160
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         426
FT                   /note="Phosphoserine; by PLK1"
FT                   /evidence="ECO:0000269|PubMed:12738781"
FT   MOD_RES         469
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         482
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         495
FT                   /note="Phosphothreonine; by PLK1"
FT                   /evidence="ECO:0000269|PubMed:12738781,
FT                   ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         1..9
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046846"
FT   VAR_SEQ         5..73
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046847"
FT   VAR_SEQ         439..499
FT                   /note="SLSPEAVLARTVGSTSTPRSRCTPRDALDLSDINSEPPRGSFPSFEPRNLLS
FT                   LFEDTLDPT -> GHPPCLACPPAGLHSPLRLSWPGLWGAPPPPGAGAHPGMPWT (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045699"
FT   VARIANT         103
FT                   /note="E -> Q (in dbSNP:rs55834293)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041034"
FT   VARIANT         140
FT                   /note="R -> C (in dbSNP:rs4149796)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4"
FT                   /id="VAR_019928"
FT   VARIANT         246
FT                   /note="R -> H (in dbSNP:rs35192104)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041035"
FT   VARIANT         351
FT                   /note="E -> K (in dbSNP:rs56382954)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041036"
FT   VARIANT         417
FT                   /note="P -> R (in dbSNP:rs4149800)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_019929"
FT   VARIANT         445
FT                   /note="V -> A (in dbSNP:rs10546)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_019930"
FT   MUTAGEN         238
FT                   /note="N->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10373560"
FT   MUTAGEN         251
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10504341"
FT   MUTAGEN         486..488
FT                   /note="RNL->AAA: Loss of CDC2-CCNB1 interaction."
FT                   /evidence="ECO:0000269|PubMed:10373560"
FT   CONFLICT        131
FT                   /note="E -> A (in Ref. 4; BAG53500)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        415
FT                   /note="G -> D (in Ref. 1; AAB71843)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        427
FT                   /note="L -> F (in Ref. 1; AAB71843)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        491
FT                   /note="L -> M (in Ref. 1; AAB71843)"
FT                   /evidence="ECO:0000305"
FT   STRAND          84..87
FT                   /evidence="ECO:0007829|PDB:5VD1"
FT   STRAND          101..103
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           105..109
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          110..119
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          122..129
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   TURN            130..132
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          135..144
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           148..164
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          173..179
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          182..188
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           194..201
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           207..226
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           236..238
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          239..241
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           243..245
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          247..249
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           252..254
FT                   /evidence="ECO:0007829|PDB:5VD0"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   STRAND          261..263
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   TURN            271..273
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           276..280
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           286..301
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           309..315
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   TURN            316..318
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           322..325
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           330..339
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   TURN            344..346
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           350..354
FT                   /evidence="ECO:0007829|PDB:5VCZ"
FT   HELIX           357..359
FT                   /evidence="ECO:0007829|PDB:5VCZ"
SQ   SEQUENCE   499 AA;  54521 MW;  4DF28A5965265567 CRC64;
     MLERPPALAM PMPTEGTPPP LSGTPIPVPA YFRHAEPGFS LKRPRGLSRS LPPPPPAKGS
     IPISRLFPPR TPGWHQLQPR RVSFRGEASE TLQSPGYDPS RPESFFQQSF QRLSRLGHGS
     YGEVFKVRSK EDGRLYAVKR SMSPFRGPKD RARKLAEVGS HEKVGQHPCC VRLEQAWEEG
     GILYLQTELC GPSLQQHCEA WGASLPEAQV WGYLRDTLLA LAHLHSQGLV HLDVKPANIF
     LGPRGRCKLG DFGLLVELGT AGAGEVQEGD PRYMAPELLQ GSYGTAADVF SLGLTILEVA
     CNMELPHGGE GWQQLRQGYL PPEFTAGLSS ELRSVLVMML EPDPKLRATA EALLALPVLR
     QPRAWGVLWC MAAEALSRGW ALWQALLALL CWLWHGLAHP ASWLQPLGPP ATPPGSPPCS
     LLLDSSLSSN WDDDSLGPSL SPEAVLARTV GSTSTPRSRC TPRDALDLSD INSEPPRGSF
     PSFEPRNLLS LFEDTLDPT
//
